SAN DIEGO, CA--(Marketwire - July 08, 2011) - Medistem Inc. (PINKSHEETS: MEDS) reported today publication of a peer-reviewed manuscript in collaboration with the Tissue Engineering, Regenerative Medicine and Cell Therapies Laboratory, CUCAIBA, of the Argentinean Ministry of Health describing a previously unreported link between metabolic syndrome, lipodystrophy, and aging. The paper, which appeared in the journal Stem Cells International (link to paper http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118295/pdf/SCI2011-943216.pdf) describes how mesenchymal stem cell exhaustion and redistribution may be an underlying theme in aging. The authors describe the possibility of addressing age-associated degeneration using "universal donor" stem cells. The clinical use of Medistem's Endometrial Regenerative Cell (ERC) is cited in the publication.
"Our group has had a productive collaboration with Medistem for over 4 years now, including publishing on the first use of the company's Endometrial Regenerative Cells in humans http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118295/pdf/SCI2011-943216.pdf," said Professor Eduardo Mansilla. "In the current paper we describe the scientific basis for how mesenchymal stem cells, such as the ERC, may be useful in the treatment of metabolic syndrome and possibly aging."
Endometrial Regenerative Cells are a type of specialized mesenchymal stem cells that originate from the lining of the uterus and are highly angiogenic. Medistem is currently developing these cells as a treatment for critical limb ischemia and heart failure, conditions that benefit from stimulation of new blood vessels.
"It is a great honor to work with Dr. Mansilla's group on diverse areas ranging from porcine burn models, to intelligent matrices, to tackling the problem of aging," said Thomas Ichim, CEO of Medistem. "Through such international collaborations Medistem is exposed to the cutting edge of research, while at the same time developing new uses of its stem cells. This is our sixth publication in the peer reviewed literature with Dr. Mansilla's group."
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.